STOCK TITAN
  1. Home
  2. Sec-filings
  3. BIO
  4. [Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity

Bio-Rad EVP acquires 425 shares via RSU vesting

Bio-Rad executive James Barry had RSUs vest into Class A common shares, with a portion of the new shares withheld to satisfy costs linked to the vesting.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BIO-RAD LABORATORIES, INC. (BIO) reported that executive vice president James Barry had restricted stock units vest into Bio-Rad Class A common stock on September 1, 2026. A total of 425 shares of Class A common stock were acquired upon RSU vesting, and 154 shares were delivered or withheld to cover the exercise price or tax liability. The RSUs converted included blocks of 174 and 251 units, each representing a right to receive one share of Class A common stock. No transactions are reported as made under a Rule 10b5-1 trading plan.

Positive

  • None.

Negative

  • None.
Insider BARRY JAMES
Role EVP, President, LSG
Type Security Shares Price Value
Exercise Restricted Stock Units F2, F3 174 $0.00 $0.00
Exercise Restricted Stock Units F2, F4 251 $0.00 $0.00
Exercise Bio-Rad A Common Stock F1 425 $0.00 $0.00
Exercise Price or Tax Liability Bio-Rad A Common Stock 154 $380.96 $59K
Holdings After Transaction: Restricted Stock Units — 251 contracts (Direct); Bio-Rad A Common Stock — 780.682 shares (Direct)
Footnotes (4)
  1. F1. Shares of Class A common stock acquired on the vesting of restricted stock units.
  2. F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  3. F3. On September 1, 2022, the reporting person was granted 694 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
  4. F4. On September 1, 2023, the reporting person was granted 1,002 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
RSUs converted (2022 grant tranche) 174 units Portion of 694-unit RSU grant dated September 1, 2022, vesting in four equal annual installments
RSUs converted (2023 grant tranche) 251 units Portion of 1,002-unit RSU grant dated September 1, 2023, vesting in four equal annual installments
Shares of Bio-Rad Class A common stock acquired on vesting 425 shares Shares acquired by James Barry on September 1, 2026 upon RSU vesting
Shares delivered or withheld for exercise price or tax liability 154 shares Bio-Rad Class A common stock, transaction code F on September 1, 2026
Per-share value for withheld shares $380.96 per share Price reported for 154 shares delivered or withheld for exercise price or tax liability
Original RSU grant (2022) 694 units RSUs granted on September 1, 2022, vesting in four equal annual installments
Original RSU grant (2023) 1,002 units RSUs granted on September 1, 2023, vesting in four equal annual installments
Restricted Stock Units financial
"On September 1, 2022, the reporting person was granted 694 restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share"
Bio-Rad Class A common stock financial
"Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock"
exercise price or tax liability financial
"Payment of exercise price or tax liability by delivering or withholding securities"

FAQ

What insider equity activity did BIO (Bio-Rad Laboratories, Inc.) report for James Barry?
The company reported that James Barry had 425 shares of Bio-Rad Class A common stock acquired on September 1, 2026 upon the vesting and conversion of restricted stock units, with a portion of those shares delivered or withheld to cover the exercise price or tax liability.

How many restricted stock units vested for the Bio-Rad (BIO) executive in this Form 4?
Two blocks of restricted stock units vested and were converted: 174 units from a 694-unit grant dated September 1, 2022, and 251 units from a 1,002-unit grant dated September 1, 2023, with each unit representing one share of Bio-Rad Class A common stock.

How many Bio-Rad (BIO) Class A shares were withheld or delivered to cover costs?
A total of 154 shares of Bio-Rad Class A common stock were delivered or withheld at $380.96 per share in connection with the vesting, to pay the exercise price or associated tax liability as reported in the Form 4.

Were James Barry’s Bio-Rad (BIO) transactions under a Rule 10b5-1 trading plan?
No. The Form 4 indicates that no Rule 10b5-1 trading plan is reported for these transactions involving the vesting and conversion of restricted stock units into Class A common stock.

What role does James Barry hold at Bio-Rad (BIO) in this Form 4?
James Barry is identified as an officer of Bio-Rad Laboratories, Inc., serving as EVP, President, LSG, in connection with the reported restricted stock unit vesting and related share transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BARRY JAMES
(Last)(First)(Middle)
C/O BIO-RAD LABORATORIES, INC.
1000 ALFRED NOBEL DRIVE
(Street)
HERCULES CALIFORNIA 94547
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, President, LSG
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Bio-Rad A Common Stock09/01/2026M425(1)A$0934.682D
Bio-Rad A Common Stock09/01/2026F154D$380.96780.682D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$0(2)09/01/2026M174 (3) (3)Bio-Rad A Common Stock174$00D
Restricted Stock Units$0(2)09/01/2026M251 (4) (4)Bio-Rad A Common Stock251$0251D
Explanation of Responses:
1. Shares of Class A common stock acquired on the vesting of restricted stock units.
2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
3. On September 1, 2022, the reporting person was granted 694 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
4. On September 1, 2023, the reporting person was granted 1,002 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
Remarks:
/s/ James Barry09/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR